Hepatic Oncology

Aims & Scope

Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease.

Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection.

Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future.

In addition, metastatic tumors of the liver are more common than primary disease.

Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors.

Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations.

The journal also highlights significant advances in basic and translational research, and places them in context for future therapy.

Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts.

The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts.

Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,195.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Mechanisms of doxorubicin resistance in hepatocellular carcinoma

  Citation: 138

  Authors: Josiah, Steven

• JAK/STAT signaling in hepatocellular carcinoma

  Citation: 116

  Authors: Justin Jit, Dexter Kai, Jhin Jieh, Tan Boon

• Molecular classification of hepatocellular carcinoma: potential therapeutic implications

  Citation: 95

  Authors: Nicolas, Xiaochen, Yujin

• Hepatocellular carcinoma treatment: hurdles, advances and prospects

  Citation: 81

  Authors: Ratna, Manoj Kumar, Anindita, Kanishka, Manas

• Dysregulated Fatty Acid Metabolism in Hepatocellular Carcinoma

  Citation: 76

  Authors: Mingda, Jun, Hao, Han, Zhenli, Lei, Chao, Shuyang, Mengchao, Feng, Tian

• Biomarker development for hepatocellular carcinoma early detection: current and future perspectives

  Citation: 58

  Authors: Shreya, Neehar D

• The role of the innate immune system in the development and treatment of hepatocellular carcinoma

  Citation: 54

  Authors: Christoph, Alexander, Münevver, Moritz, Frank

• Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

  Citation: 52

  Authors: Abdalla, Sarah, Dipen, Yunes, Fernando

• STAT3 in hepatocellular carcinoma: new perspectives

  Citation: 51

  Authors: Jasmin, Wolfgang, Robert

• Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review

  Citation: 43

  Authors: Sebastiao N, Juan